A biosimilar is a biologic product that is similar to a regulatory body approved reference product, and has no clinically meaningful differences in terms of safety and effectiveness from that reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry. Furthermore, the recent approval of three biosimilars in the US market is providing an impetus to more biopharmaceutical companies to enter this field. As per RNCOS report "Global Biosimilar Market Outlook 2022", the global biosimilars market is anticipated to witness a high double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global biosimilars market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global biosimilars market. The global biosimilars market has been segmented on the basis of type of product. The major types of biosimilars present in the market include monoclonal antibodies, erythropoietin, insulin, G-CSF, HGH, and interferon amongst others. The report also highlights the various biosimilar drugs available in the market, and the biosimilars currently in various phases of clinical trials. Furthermore, the global biosimilars market has also been segmented on the basis of their applications. According to the report, oncology is expected to account for the largest share in 2016 due to presence of large number of biosimilars for this indication. Based on geography, the report divides the market into Europe, Asia-Pacific, North America and Rest of the World. In 2016, Europe is expected to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global biosimilars industry. The last section of the report discusses about the prominent players in global biosimilars market. Market share analysis of these players is also provided in the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and clinical pipelines. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global biosimilars market.
Table of Contents
1. Analyst View 2. Research Methodology 3. Global Biosimilars Market Outlook 2022 4. Market Dynamics 4.1 Drivers 4.1.1 Growing Geriatric Population 4.1.2 Entry of Biosimilars in the US Market 4.1.3 Ability to Curb Healthcare Cost 4.1.4 Rising Incidences of Chronic Diseases 4.1.5 Government Initiatives 4.2 Challenges 4.2.1 Regulatory Issues 4.2.2 Greater Litigation Risk 4.2.3 Lack of Standardized Manufacturing Process 4.3 Opportunities 4.3.1 Emerging Markets - Area of Opportunities for Biosimilars 4.3.2 Patent Expiry of Blockbuster Biologics 5. Market Segmentation by Product Type 5.1 Erythropoietin (EPO) 5.2 Human Growth Hormone (HGH) 5.3 Granulocyte- Colony Stimulating Factor (G-CSF) 5.4 Monoclonal Antibody (mAb) 5.5 Insulin 5.6 Interferon (IFN) 5.7 Others 6. Market Segmentation by Geography 6.1 Europe 6.1.1 Germany 6.1.2 France 6.1.3 Italy 6.1.4 Spain 6.1.5 UK 6.2 Asia-Pacific 6.2.1 India 6.2.2 China 6.2.3 Japan 6.3 North America 6.3.1 US 6.3.2 Canada 6.4 Rest of the World 7. Market Segmentation by Applications 7.1 Oncology 7.2 Blood Disorders 7.3 Others 8. Market Trends and Developments 8.1 Development of Modular Biosimilar Plants 8.2 Biosimilars in Oncology 9. Mergers and Acquisitions 10. Porter's Five Forces Analysis 11. Competitive Landscape 11.1 Market Share of Major Players 11.2 Company Profiles 11.2.1 Biocad 11.2.2 Celltrion Inc. 11.2.3 Dong-A Socio Group 11.2.4 Pfizer Inc. 11.2.5 Intas Pharmaceuticals Ltd. 11.2.6 Sandoz International GmbH - A Novartis Company 11.2.7 Stada Arzneimittel AG 11.2.8 Teva Pharmaceutical Industries Ltd. 11.2.9 Amgen Inc. 11.2.10 Biocon 12. Future Outlook
List of Tables: Table 5-1: Global - Biosimilar EPOs Approved for Marketing Table 5-2: Global - Biosimilar EPOs in Pipeline Table 5-3: Global - Biosimilar HGH Approved for Marketing Table 5-4: Global - Biosimilar HGH in Pipeline Table 5-5: Global - Biosimilar G-CSF Approved for Marketing Table 5-6: Global - Biosimilar G-CSF in Pipeline Table 5-7: Global - Biosimilar mAbs Approved for Marketing Table 5-8: Global - Biosimilar mAbs in Pipeline Table 5-9: Global - Biosimilar Insulin Approved for Marketing Table 5-10: Global - Biosimilar Insulin in Pipeline Table 5-11: Global - Biosimilar Interferons Approved for Marketing Table 5-12: Global - Biosimilar Interferons in Pipeline Table 9-1: Global - Major M&A in the Biosimilar Industry (2014-2016) Table 11-1: Biocad - Major Biosimilars Approved for Marketing Table 11-2: Biocad - Major Biosimilars in Pipeline Table 11-3: Celltrion Inc. - Revenue (Million US$), 2013, 2014 & 2015 Table 11-4: Celltrion Inc. - Major Biosimilars Approved for Marketing Table 11-5: Celltrion Inc. - Major Biosimilars in Pipeline Table 11-6: Dong-A Socio Group - Revenue (Million US$), 2013, 2014 & 2015 Table 11-7: Dong-A Socio Group - Major Biosimilars in Pipeline Table 11-8: Pfizer Inc. - Revenue (Million US$), 2013, 2014 & 2015 Table 11-9: Pfizer Inc. - Major Biosimilars Approved for Marketing Table 11-10: Pfizer Inc. - Major Biosimilars in Pipeline Table 11-11: Intas Pharmaceutical Ltd. - Revenue (Million US$), FY2013, FY2014 & FY2015 Table 11-12: Intas Pharmaceuticals Ltd. - Major Biosimilars Approved for Marketing Table 11-13: Intas Pharmaceuticals Ltd. - Major Biosimilars in Pipeline Table 11-14: Sandoz International GmbH - Revenue (Million US$), 2013, 2014 & 2015 Table 11-15: Sandoz International GmbH - Major Biosimilars Approved for Marketing Table 11-16: Sandoz International GmbH - Major Biosimilars in Pipeline Table 11-17: Stada Arzneimittel AG - Group Sales (Million US$), 2013, 2014 & 2015 Table 11-18: Stada Arzneimittel AG - Major Biosimilars Approved for Marketing Table 11-19: Stada Arzneimittel AG - Major Biosimilars in Pipeline Table 11-20: Teva Pharmaceutical Industries Ltd. - Net Sales (Million US$), 2013, 2014 & 2015 Table 11-21: Teva Pharmaceutical Industries Ltd. - Major Biosimilars Approved for Marketing Table 11-22: Amgen Inc. - Total Company Revenue (Million US$), 2013, 2014 & 2015 Table 11-23: Amgen Inc. - Major Biosimilars in Pipeline Table 11-24: Biocon - Revenue (Million US$), FY2014, FY2015 & FY2016 Table 11-25: Biocon - Major Biosimilars Approved for Marketing Table 11-26: Biocon - Major Biosimilars in Pipeline
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.